Comparative Pharmacology
Head-to-head clinical analysis: DROSPIRENONE versus PROMETRIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DROSPIRENONE versus PROMETRIUM.
DROSPIRENONE vs PROMETRIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Spironolactone analog that antagonizes aldosterone at the mineralocorticoid receptor, leading to increased sodium and water excretion and potassium retention. Also has antiandrogenic activity by blocking androgen receptors and decreasing ovarian androgen production via inhibition of gonadotropin release.
Progesterone binds to progesterone receptors in target tissues, promoting endometrial maturation, reducing uterine contractility, and suppressing ovulation.
3 mg orally once daily.
Oral: 200 mg once daily at bedtime for 12 consecutive days per 28-day cycle in combination with conjugated estrogens 0.625 mg daily. For secondary amenorrhea: 400 mg once daily at bedtime for 10 days. Intravaginal: 4% gel (90 mg) or 8% gel (180 mg) applied every other day for 6 doses in postmenopausal women with intact uterus on estrogen therapy.
None Documented
None Documented
Clinical Note
moderateDrospirenone + Benzydamine
"Drospirenone may increase the hyperkalemic activities of Benzydamine."
Clinical Note
moderateDrospirenone + Droxicam
"Drospirenone may increase the hyperkalemic activities of Droxicam."
Clinical Note
moderateDrospirenone + Loxoprofen
"Drospirenone may increase the hyperkalemic activities of Loxoprofen."
Clinical Note
moderateDrospirenone + Clonixin
"Drospirenone may increase the hyperkalemic activities of Clonixin."
Terminal elimination half-life: ~30-35 hours (range 25-40 h); significant clinical accumulation occurs after repeated dosing, requiring 10-14 days to reach steady state.
Terminal half-life: Approximately 16-18 hours for oral micronized progesterone (Prometrium); permits twice-daily dosing for luteal phase support.
Renal: ~50% (as metabolites; <10% unchanged); Fecal: ~40-50% (as metabolites; bile-mediated); Urinary and fecal elimination account for >95% of an oral dose.
Urine (50-60% as metabolites, <1% unchanged); feces (20-30% as metabolites); minor biliary elimination.
Category C
Category C
Progestin
Progestin